UCLA's AlloESO-T cell therapy targets solid tumors at an estimated $5,000 per dose — a fraction of current costs — but remains in preclinical mouse trials only.

Sept 8 (Reuters) - Bristol Myers Squibb said on Tuesday its experimental cell therapy showed a high overall response rate in ...

A new MS cell therapy uses a patient's own red blood cells to retrain the immune system, helping protect myelin and reduce ...

SEOUL, South Korea - August 31, 2026 - As treatment options for orthopedic conditions continue to evolve, more patients ...

New research is helping veterinarians understand how stem cells promote healing, when they should be used, and which ...

CAR T-cell therapy is an immune-reprogramming procedure that turns a patient's own immune cells into cancer-fighting ...

Realizing the potential of cell and gene therapies will require organizations to rethink how they finance care and build the ...

For people recently diagnosed with multiple sclerosis (MS), early treatment choices were associated with only slight ...

Therapy planning shifted from intended autologous transplant to CAR-T; detailed counseling helped align expectations and ...

Researchers from the University of Miami Miller School of Medicine and collaborating institutions have published a ...

Seattle biotech BrainChild Bio has raised $116 million to advance an experimental CAR T cell therapy for DIPG, a rare and deadly brain tumor that primarily affects young children. The company is ...

Arlo-cel uses autologous T-cell collection, ex vivo CAR engineering, lymphodepletion, and single infusion, necessitating infrastructure for manufacturing logistics and post-infusion monitoring. Safety ...